Pfizer Inc. (PFE)
After hours:
| Previous Close | 53.37 |
| Open | 53.77 |
| Bid | 54.51 x 1400 |
| Ask | 54.60 x 2200 |
| Day's Range | 53.10 - 54.67 |
| 52 Week Range | 33.36 - 61.71 |
| Volume | |
| Avg. Volume | 45,653,990 |
| Market Cap | 304.947B |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | 15.52 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.60 (2.94%) |
| Ex-Dividend Date | Jan. 27, 2022 |
| 1y Target Est | N/A |
- Business Wire
European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer
NEW YORK, January 28, 2022--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) granted marketing authorization for LORVIQUA® (lorlatinib, available in the U.S. under the brand name LORBRENA®) as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.
- Business Wire
Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment
NEW YORK, January 27, 2022--Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional marketing authorization (CMA) of Pfizer’s PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.
- Business Wire
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
NEW YORK & MAINZ, Germany, January 25, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidate in healthy adults 18 through 55 years of age. The study will have three cohorts examining different regimens of the current Pfizer-BioNTech COVID-19 vaccine or an Omicron-based vaccine. The study will draw upon some participants from the companies’ Phase
